+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gynecology Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018-2026

  • ID: 4851841
  • Report
  • January 2019
  • Region: Global
  • 213 pages
  • Transparency Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

Global Gynecology Drugs market: Overview

This report analyzes the current and future scenario of the global gynecology drugs market. High incidence and prevalence of gynecology diseases and rise in patient awareness are major drivers of the global market.

The global gynecology drugs market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to segments based on therapeutics, indication, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global gynecology drugs market.

Global Gynecology Drugs Market: Key Segments

The global gynecology drugs market has been segmented based on therapeutics, indication, distribution channel, and region. Furthermore, in terms of therapeutics, the market has been divided into hormonal therapy and non-hormonal therapy. The non-hormonal therapy segment is likely to account for a leading share of the global market during the forecast period owing to the effectiveness of the products, rise in adoption of these products, and new product development. Decreasing use of hormonal products due to the risk of breast cancer has boosted the demand for non-hormonal pharmaceutical products. In terms of indication, the global market has been classified into gynecology cancers, endometriosis, female infertility, menopausal disorder, gynecology infections, polycystic ovary syndrome, contraception (birth control), and others. In terms of distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is estimated to expand at a significant CAGR during forecast period, owing to the ease of use of online pharmacies and a rise in the number of internet users. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Gynecology Drugs Market: Regional Outlook

In terms of region, the global gynecology drugs market has been segmented into five major regions and key countries/sub-regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global gynecology drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players in the global gynecology drugs market are Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc, Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Allergan Plc, and Bayer AG.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary
3.1. Global Gynecology Drugs Market: Market Snapshot

4. Market Overview
4.1. Global Gynecology Drugs Market: Product Overview
4.2. Global Gynecology Drugs Market: Key Industry Developments
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gynecology Drugs Market Revenue Projections, 2016-2026
4.5. Porter’s Five Forces Analysis
4.6. Global Gynecology Drugs Market Outlook

5. Market Outlook
5.1. Regulatory Scenario
5.2. Disease Prevalence
5.3. Pipeline Analysis

6. Global Gynecology Drugs Market Analysis, by Therapeutics
6.1. Key Findings
6.2. Introduction
6.3. Global Gynecology Drugs Market Value Share, by Therapeutics
6.4. Global Gynecology Drugs Market Value Forecast, by Therapeutics
6.4.1. Hormonal Therapy
6.4.1.1. Estrogen Therapy
6.4.1.2. Progestin Therapy
6.4.1.3. Combination Therapy
6.4.1.4. Thyroid Replacement Therapy
6.4.1.5. Parathyroid Hormone Therapy
6.4.1.6. Others
6.4.2. Non-hormonal Therapy
6.4.2.1. Anti-Infective Agents
6.4.2.2. Anti-neoplastic Agents
6.4.2.3. Anti-inflammatory Agents
6.4.2.4. Others
6.5. Global Gynecology Drugs Market Analysis, by Therapeutics
6.6. Global Gynecology Drugs Market Attractiveness Analysis, by Therapeutics

7. Global Gynecology Drugs Market Analysis, by Indication
7.1. Key Findings
7.2. Introduction
7.3. Global Gynecology Drugs Market Value Share, by Indication
7.4. Global Gynecology Drugs Market Value Forecast, by Indication
7.4.1.1. Gynecology Cancers
7.4.1.2. Endometriosis
7.4.1.3. Female Infertility
7.4.1.4. Menopausal Disorder
7.4.1.5. Gynecology Infections
7.4.1.6. Polycystic Ovary Syndrome
7.4.1.7. Contraception (Birth Control)
7.4.1.8. Others
7.5. Global Gynecology Drugs Market Analysis, by Indication
7.6. Global Gynecology Drugs Market Attractiveness Analysis, by Indication

8. Global Gynecology Drugs Market Analysis, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Global Gynecology Drugs Market Value Share, by Distribution Channel
8.4. Global Gynecology Drugs Market Value Forecast, by Distribution Channel
8.4.1. Hospital Pharmacies
8.4.2. Retail Pharmacies
8.4.3. Online Pharmacies
8.5. Global Gynecology Drugs Market Analysis, by Distribution Channel
8.6. Global Gynecology Drugs Market Attractiveness Analysis, by Distribution Channel

9. Global Gynecology Drugs Market Analysis, by Region
9.1. Global Gynecology Drugs Market Scenario, by Country
9.2. Global Gynecology Drugs Market Value Share, by Region
9.3. Global Gynecology Drugs Market Value Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Global Gynecology Drugs Market Attractiveness Analysis, by Region

10. North America Gynecology Drugs Market Analysis
10.1. Key Findings
10.2. North America Gynecology Drugs Market Overview
10.3. North America Gynecology Drugs Market Value Share, by Country
10.4. North America Gynecology Drugs Market Forecast, by Country
10.4.1. U.S.
10.4.2. Canada
10.5. North America Gynecology Drugs Market Value Share Analysis, by Therapeutics
10.6. North America Gynecology Drugs Market Forecast, by Therapeutics
10.6.1. Hormonal Therapy
10.6.1.1. Estrogen Therapy
10.6.1.2. Progestin Therapy
10.6.1.3. Combination Therapy
10.6.1.4. Thyroid Replacement Therapy
10.6.1.5. Parathyroid Hormone Therapy
10.6.1.6. Others
10.6.2. Non-hormonal Therapy
10.6.2.1. Anti-Infective Agents
10.6.2.2. Anti-neoplastic Agents
10.6.2.3. Anti-inflammatory Agents
10.6.2.4. Others
10.7. North America Gynecology Drugs Market Value Share Analysis, by Indication
10.8. North America Gynecology Drugs Market Forecast, by Indication
10.8.1. Gynecology Cancers
10.8.2. Endometriosis
10.8.3. Female Infertility
10.8.4. Menopausal Disorder
10.8.5. Gynecology Infections
10.8.6. Polycystic Ovary Syndrome
10.8.7. Contraception (Birth Control)
10.8.8. Others
10.9. North America Gynecology Drugs Market Value Share Analysis, by Distribution Channel
10.10. North America Gynecology Drugs Market Forecast, by Distribution Channel
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacies
10.10.3. Online Pharmacies
10.11. North America Gynecology Drugs Market Attractiveness Analysis

11. Europe Gynecology Drugs Market Analysis
11.1. Key Findings
11.2. Europe Gynecology Drugs Market Overview
11.3. Europe Gynecology Drugs Market Value Share, by Country/Sub-region
11.4. Europe Gynecology Drugs Market Forecast, by Country/Sub-region
11.4.1. UK
11.4.2. Germany
11.4.3. France
11.4.4. Italy
11.4.5. Spain
11.4.6. Rest of Europe
11.5. Europe Gynecology Drugs Market Value Share Analysis, by Therapeutics
11.6. Europe Gynecology Drugs Market Forecast, by Therapeutics
11.6.1. Hormonal Therapy
11.6.1.1. Estrogen Therapy
11.6.1.2. Progestin Therapy
11.6.1.3. Combination Therapy
11.6.1.4. Thyroid Replacement Therapy
11.6.1.5. Parathyroid Hormone Therapy
11.6.1.6. Others
11.6.2. Non-hormonal Therapy
11.6.2.1. Anti-Infective Agents
11.6.2.2. Anti-neoplastic Agents
11.6.2.3. Anti-inflammatory Agents
11.6.2.4. Others
11.7. Europe Gynecology Drugs Market Value Share Analysis, by Indication
11.8. Europe Gynecology Drugs Market Forecast, by Indication
11.8.1. Gynecology Cancers
11.8.2. Endometriosis
11.8.3. Female Infertility
11.8.4. Menopausal Disorder
11.8.5. Gynecology Infections
11.8.6. Polycystic Ovary Syndrome
11.8.7. Contraception (Birth Control)
11.8.8. Others
11.9. Europe Gynecology Drugs Market Value Share Analysis, by Distribution Channel
11.10. Europe Gynecology Drugs Market Forecast, by Distribution Channel
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Online Pharmacies
11.11. Europe Gynecology Drugs Market Attractiveness Analysis

12. Asia Pacific Gynecology Drugs Market Analysis
12.1. Key Findings
12.2. Asia Pacific Gynecology Drugs Market Overview
12.3. Asia Pacific Gynecology Drugs Market Value Share, by Country/Sub-region
12.4. Asia Pacific Gynecology Drugs Market Forecast, by Country/Sub-region
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Therapeutics
12.6. Asia Pacific Gynecology Drugs Market Forecast, by Therapeutics
12.6.1. Hormonal Therapy
12.6.1.1. Estrogen Therapy
12.6.1.2. Progestin Therapy
12.6.1.3. Combination Therapy
12.6.1.4. Thyroid Replacement Therapy
12.6.1.5. Parathyroid Hormone Therapy
12.6.1.6. Others
12.6.2. Non-hormonal Therapy
12.6.2.1. Anti-Infective Agents
12.6.2.2. Anti-neoplastic Agents
12.6.2.3. Anti-inflammatory Agents
12.6.2.4. Others
12.7. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Indication
12.8. Asia Pacific Gynecology Drugs Market Forecast, by Indication
12.8.1. Gynecology Cancers
12.8.2. Endometriosis
12.8.3. Female Infertility
12.8.4. Menopausal Disorder
12.8.5. Gynecology Infections
12.8.6. Polycystic Ovary Syndrome
12.8.7. Contraception (Birth Control)
12.8.8. Others
12.9. Asia Pacific Gynecology Drugs Market Value Share Analysis, by Distribution Channel
12.10. Asia Pacific Gynecology Drugs Market Forecast, by Distribution Channel
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Pharmacies
12.11. Asia Pacific Gynecology Drugs Market Attractiveness Analysis

13. Latin America Gynecology Drugs Market Analysis
13.1. Key Findings
13.2. Latin America Gynecology Drugs Market Overview
13.3. Latin America Gynecology Drugs Market Value Share, by Country/Sub-region
13.4. Latin America Gynecology Drugs Market Forecast, by Country/Sub-region
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Gynecology Drugs Market Value Share Analysis, by Therapeutics
13.6. Latin America Gynecology Drugs Market Forecast, by Therapeutics
13.6.1. Hormonal Therapy
13.6.1.1. Estrogen Therapy
13.6.1.2. Progestin Therapy
13.6.1.3. Combination Therapy
13.6.1.4. Thyroid Replacement Therapy
13.6.1.5. Parathyroid Hormone Therapy
13.6.1.6. Others
13.6.2. Non-hormonal Therapy
13.6.2.1. Anti-Infective Agents
13.6.2.2. Anti-neoplastic Agents
13.6.2.3. Anti-inflammatory Agents
13.6.2.4. Others
13.7. Latin America Gynecology Drugs Market Value Share Analysis, by Indication
13.8. Latin America Gynecology Drugs Market Forecast, by Indication
13.8.1. Gynecology Cancers
13.8.2. Endometriosis
13.8.3. Female Infertility
13.8.4. Menopausal Disorder
13.8.5. Gynecology Infections
13.8.6. Polycystic Ovary Syndrome
13.8.7. Contraception (Birth Control)
13.8.8. Others
13.9. Latin America Gynecology Drugs Market Value Share Analysis, by Distribution Channel
13.10. Latin America Gynecology Drugs Market Forecast, by Distribution Channel
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Pharmacies
13.11. Latin America Gynecology Drugs Market Attractiveness Analysis

14. Middle East & Africa Gynecology Drugs Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Gynecology Drugs Market Overview
14.3. Middle East & Africa Gynecology Drugs Market Value Share, by Country/Sub-region
14.4. Middle East & Africa Gynecology Drugs Market Forecast, by Country/Sub-region
14.4.1. GCC
14.4.2. South Africa
14.4.3. Rest of MEA
14.5. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Therapeutics
14.6. Middle East & Africa Gynecology Drugs Market Forecast, by Therapeutics
14.6.1. Hormonal Therapy
14.6.1.1. Estrogen Therapy
14.6.1.2. Progestin Therapy
14.6.1.3. Combination Therapy
14.6.1.4. Thyroid Replacement Therapy
14.6.1.5. Parathyroid Hormone Therapy
14.6.1.6. Others
14.6.2. Non-hormonal Therapy
14.6.2.1. Anti-Infective Agents
14.6.2.2. Anti-neoplastic Agents
14.6.2.3. Anti-inflammatory Agents
14.6.2.4. Others
14.7. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Indication
14.8. Middle East & Africa Gynecology Drugs Market Forecast, by Indication
14.8.1. Gynecology Cancers
14.8.2. Endometriosis
14.8.3. Female Infertility
14.8.4. Menopausal Disorder
14.8.5. Gynecology Infections
14.8.6. Polycystic Ovary Syndrome
14.8.7. Contraception (Birth Control)
14.8.8. Others
14.9. Middle East & Africa Gynecology Drugs Market Value Share Analysis, by Distribution Channel
14.10. Middle East & Africa Gynecology Drugs Market Forecast, by Distribution Channel
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Pharmacies
14.11. Middle East & Africa Gynecology Drugs Market Attractiveness Analysis

15. Competition Landscape
15.1. Gynecology Drugs Market Share Analysis, by Company, 2017
15.2. Competition Matrix
15.3. Company Profiles
15.3.1. Allergan plc.
15.3.1.1. Company Details
15.3.1.2. Business Overview
15.3.1.3. Financial Overview
15.3.1.4. Strategic Overview
15.3.1.5. SWOT Analysis
15.3.2. Amgen Inc.
15.3.2.1. Company Details
15.3.2.2. Business Overview
15.3.2.3. Financial Overview
15.3.2.4. Strategic Overview
15.3.2.5. SWOT Analysis
15.3.3. Bayer AG
15.3.3.1. Company Details
15.3.3.2. Business Overview
15.3.3.3. Financial Overview
15.3.3.4. Strategic Overview
15.3.3.5. SWOT Analysis
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Details
15.3.4.2. Business Overview
15.3.4.3. Financial Overview
15.3.4.4. Strategic Overview
15.3.4.5. SWOT Analysis
15.3.5. Pfizer Inc.
15.3.5.1. Company Details
15.3.5.2. Business Overview
15.3.5.3. Financial Overview
15.3.5.4. Strategic Overview
15.3.5.5. SWOT Analysis
15.3.6. Eli Lilly Company
15.3.6.1. Company Details
15.3.6.2. Business Overview
15.3.6.3. Financial Overview
15.3.6.4. Strategic Overview
15.3.6.5. SWOT Analysis
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1. Company Details
15.3.7.2. Business Overview
15.3.7.3. Financial Overview
15.3.7.4. Strategic Overview
15.3.7.5. SWOT Analysis
15.3.8. AstraZeneca
15.3.8.1. Company Details
15.3.8.2. Business Overview
15.3.8.3. Financial Overview
15.3.8.4. Strategic Overview
15.3.8.5. SWOT Analysis
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll